HCG Healthcare Global Enterprises Q3 FY25 results (Oct–Dec 2024) and concall
HCG reported strong Q3 FY25 results with 19% YoY revenue growth and 23% PAT growth, driven by robust performance in emerging and established oncology centers. Despite seasonal weakness and geopolitical impacts on international patient volumes, the company maintained a healthy 16.5% adjusted EBITDA margin. Management expressed confidence in continued growth, margin expansion, and the strategic partnership with KKR to drive long-term expansion and focus on precision oncology and research.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 |
|---|---|---|
| Revenue | 554 | 559 |
| EBITDA | 102 | 88 |
| Net profit | 21 | 8 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
